Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsOscar Health Adefovir Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentOscar HealthPolicy PG081

    Adefovir Dipivoxil (Hepsera)

    Customize your policy alerts

    Sign up for Oscar Health Policy PG081 alerts

    Get alerted when Policy PG081 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This guideline governs prior authorization, initial coverage, and reauthorization of oral adefovir dipivoxil (Hepsera) for members with chronic hepatitis B virus infection. It requires specialist involvement, age and diagnosis criteria, supporting documentation, and evidence of therapeutic response for continued therapy.

    Policy Summary
    PayerOscar Health
    PolicyAdefovir Dipivoxil (Hepsera)
    Policy CodePolicy PG081
    Change TypeNo material change
    Effective DateN/A
    Last ReviewJan 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation showing specialist involvement, age 12 years or older, chronic HBV infection, and inability to use or prior failure of entecavir or tenofovir alafenamide.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12+Minimum age
    6 monthsInitial authorization
    12 monthsReauthorization
    3 monthsDocumentation recency
    1 of 3Response pathways
    Not coveredOther indications

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following criteria are met. If these prior authorization criteria are met, Adefovir Dipivoxil (Hepsera) will be approved for up to 6 months.

    ALL of the following

    • The requested medication is being prescribed by or in consultation with a gastroenterologist, hepatologist, or infectious disease specialist.
    • The member is 12 years of age or older.
    • The member has a documented diagnosis of chronic hepatitis B virus (HBV) infection confirmed by appropriate laboratory test(s).
    • The member is unable to use or has tried and failed entecavir (Baraclude) or tenofovir (Vemlidy).
    Policy Summary
    PayerOscar Health
    PolicyAdefovir Dipivoxil (Hepsera)
    Policy CodePolicy PG081
    Change TypeNo material change
    Effective DateN/A
    Last ReviewJan 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation showing specialist involvement, age 12 years or older, chronic HBV infection, and inability to use or prior failure of entecavir or tenofovir alafenamide.
    SourceLink
    On This Page
    Coverage CriteriaProvider ActionsClinical BackgroundDefinitionsInitial Authorization CriteriaReauthorization CriteriaPreferred Antiviral Requirement

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Chart documentation and supporting laboratory test results are provided for review to substantiate the above listed requirements.

    Continuation Therapy / Reauthorization

    Reauthorization for up to 12 months will be granted when recent chart and laboratory test results documentation shows the member has experienced therapeutic response to the requested medication, as evidenced by at least ONE of the following.

    ALL of the following

    • Chart and laboratory test results documentation is provided from within the last 3 months.Within the last 3 months
    • ONE of the following

      • A decrease or suppression of serum HBV DNA levels (viral load, reported in international units/mL or in copies/mL) compared to baseline (pre-treatment).
      • A decrease or normalization of serum aminotransferase (ALT or AST) concentrations compared to baseline (pre-treatment).
      • Undetectable levels of serum HBV DNA or only minimal histologic evidence of liver injury.

    Adefovir Dipivoxil (Hepsera) for any indication other than chronic hepatitis B virus (HBV) infection is considered experimental, investigational, or unproven and is not covered.

    Adefovir Dipivoxil (Hepsera) for any other indication is considered not medically necessary by the Plan.

    Provider Actions

    Prior Authorization

    Initial Prior Authorization

    Submit an initial prior authorization request when Adefovir Dipivoxil (Hepsera) is prescribed by or in consultation with a gastroenterologist, hepatologist, or infectious disease specialist for a member who is at least 12 years old and has laboratory-confirmed chronic hepatitis B virus (HBV) infection. If approved, the initial authorization period is up to 6 months.

    • Specialist involvement is required.
    • Member must be 12 years of age or older.
    • Diagnosis must be chronic HBV infection confirmed by appropriate laboratory tests.
    Prior Authorization

    Reauthorization Required

    Request reauthorization for up to 12 months only when recent documentation demonstrates that the member has experienced a therapeutic response to Adefovir Dipivoxil (Hepsera).

    • Chart and laboratory results must be from within the last 3 months.
    • Therapeutic response must meet at least one of the applicable continuation criteria.
    Step Therapy

    Preferred Antiviral Trial or Inability to Use

    Document that the member has either tried and failed or is unable to use entecavir (Baraclude) or tenofovir (Vemlidy) before requesting Adefovir Dipivoxil (Hepsera).

    • Preferred antiviral options: entecavir (Baraclude) or tenofovir (Vemlidy).
    • Include the treatment failure or reason the preferred antiviral is unsuitable.

    Unsupported block type: documentation

    Unsupported block type: documentation

    Denial Risk

    Noncovered Indication

    Adefovir Dipivoxil (Hepsera) requested for any indication other than chronic hepatitis B is considered not medically necessary by the Plan because it is experimental, investigational, or unproven.

    • Noncovered indication: any indication other than chronic HBV infection.
    Denial Risk

    Failure to Meet Initial Criteria

    An initial request may be denied when the member does not meet the required specialist, age, diagnosis, preferred-antiviral, or documentation requirements.

    • No prescription by or consultation with a gastroenterologist, hepatologist, or infectious disease specialist.
    • Member is younger than 12 years of age.
    • No documented, laboratory-confirmed chronic HBV infection.
    • No documented trial and failure of, or inability to use, entecavir or tenofovir.
    • Required chart documentation or supporting laboratory results are absent.
    Denial Risk

    Insufficient Response for Reauthorization

    Reauthorization may be denied when recent evidence does not demonstrate a therapeutic response to Adefovir Dipivoxil (Hepsera).

    • Chart or laboratory documentation is not from within the last 3 months.
    • No decrease or suppression of serum HBV DNA compared with baseline.
    • No decrease or normalization of ALT or AST compared with baseline.
    • No undetectable serum HBV DNA and no more than minimal histologic evidence of liver injury.

    Clinical Background

    Chronic hepatitis B (HBV) is a viral infection that may persist and lead to cirrhosis or hepatocellular carcinoma. Treatment decisions may consider the presence of cirrhosis, alanine aminotransferase levels, and HBV DNA levels. Adefovir dipivoxil is an oral antiviral approved for chronic HBV infection in patients 12 years of age and older; however, it is not preferred for long-term treatment because of a high rate of resistance. Tenofovir or entecavir generally have a higher barrier to resistance.

    Definitions

    ALT and AST
    ASTAspartate transaminase, a liver enzyme.
    ALTAlanine aminotransferase, a liver enzyme.
    Clinical significanceAST and ALT indicate liver damage or injury from different types of diseases or conditions.
    Creatinine clearance (CrCl)
    DefinitionCreatinine clearance is the volume of blood plasma cleared of creatinine per unit of time.
    CreatinineCreatinine is a waste product from the body.
    Clinical significanceCreatinine clearance is an indicator or measurement of kidney function.
    DNA
    Full nameDNA stands for deoxyribonucleic acid.
    LocationDNA is a small molecule inside cells.
    FunctionDNA contains genetic information.
    Nucleoside analog
    Drug classA nucleoside analog is a class of drugs used to treat viral infections.
    Antiviral actionNucleoside analogs inhibit the ability of the virus to replicate.
    Clinical roleThe class works by limiting viral replication in treated infections.

    Initial Authorization Criteria

    Initial Authorization

    Initial authorization requires ALL of the following criteria and may be approved for up to 6 months.

    Initial authorization requirements

    • Specialist involvement: The requested medication is prescribed by or in consultation with a gastroenterologist, hepatologist, or infectious disease specialist.
    • Member age: The member is 12 years of age or older.>= 12 years
    • Diagnosis: The member has a documented diagnosis of chronic hepatitis B virus (HBV) infection confirmed by appropriate laboratory test(s).
    • Alternative therapy requirement: The member is unable to use or has tried and failed entecavir (Baraclude) or tenofovir (Vemlidy).
    • Documentation: Chart documentation and supporting laboratory test results are provided for review to substantiate the listed requirements.

    Reauthorization Criteria

    Reauthorization

    Reauthorization for up to 12 months requires recent chart and laboratory documentation, obtained within the last 3 months, showing therapeutic response through at least ONE accepted outcome.

    Therapeutic response

    • HBV DNA response: There is a decrease or suppression of serum HBV DNA levels compared to baseline before treatment.Decrease or suppression versus baseline

      HBV DNA may be reported in international units/mL or copies/mL.

    • Aminotransferase response: There is a decrease or normalization of serum aminotransferase (ALT or AST) concentrations compared to baseline before treatment.Decrease or normalization versus baseline
    • Virologic or histologic response: Serum HBV DNA is undetectable or there is only minimal histologic evidence of liver injury.Undetectable HBV DNA or minimal histologic evidence

    Preferred Antiviral Requirement

    StepRequirementFailure or inability-to-use criteria
    1Before initial authorization of adefovir dipivoxil (Hepsera), the member must be unable to use or have tried and failed entecavir (Baraclude) or tenofovir (Vemlidy).Document inability to use one of these alternatives or a prior trial and failure.